Inhibikase Therapeutics, Inc. (IKT) vs Scribe Therapeutics Inc. (SCTX)

A side-by-side comparison of Inhibikase Therapeutics, Inc. and Scribe Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IKT

Inhibikase Therapeutics, Inc.

$261M

$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SCTX

Scribe Therapeutics Inc.

$264M

$16.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — IKT vs SCTX

growth of $100 · dividends reinvested · last 1y

IKT -7.8% (-7.8%/yr)SCTX +8.1% (+8.1%/yr)SCTX compounded faster over this window

IKT SCTX

Metrics side by side

Total return (annualized)

Metric	IKT	SCTX
Total return (1Y)	20.37%	N/A
Total return CAGR (3Y)	30.49%	N/A
Total return CAGR (5Y)	-29.10%	N/A

SCTX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full IKT analysis Full SCTX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.